Clinical study: CBD for psychosis & excessive eating caused by antipsychotics

A new clinical study today announced by Phoenix-based biomedical company Insys Therapeutics will explore the effectiveness of the company’s patented CBD oral solution on symptoms of early psychosis and the drive behind excessive eating behaviour that accompanies the use of antipsychotic medication.

The research will be included as part of the company’s collaboration with UC San Diego’s Center for Medicinal Cannabis Research (CMCR).

“As a result of this new study announced today, we expect to learn whether CBD reduces symptoms and improves cognition in early psychosis,” said Kristin Cadenhead, MD, professor of psychiatry at UC San Diego.

“In addition, we plan to explore the effect of CBD on the biological response to psychosocial stress, and the effect of CBD on the eating behavior induced by antipsychotic medication,” said Dr. Cadenhead.

CMCR Director Igor Grant, MD said: “Cannabinoids such as CBD deserve rigorous study into their possible value in the treatment of neuropsychiatric disorders.

“We are pleased that through our collaboration with INSYS we have an opportunity to advance the field,” said Dr. Grant.

In addition to the Clinical Study of Cannabidiol in Early Psychosis, INSYS and CMCR are continuing with a study of oral CBD in pediatric patients with autism, which is expected to start in 2019.

INSYS president and CEO said the research into psychosis and autism are among several other studies that its clinical research teams are considering.

“Our partnership with CMCR has the potential to significantly advance the clinical science of pharmaceutical cannabinoids across a range of indications,” said Saeed Motahari.

INSYS also has a number of other clinical trials underway, including a phase-two study on CBD treatment for childhood absence epilepsy, another for Prader Willi Syndrome, as well as a phase three trial for infantile spasms.
The specialty pharmaceutical company develops and commercializes drugs and novel drug-delivery systems, including its proprietary spray technology.
UC San Diego’s Center for Medicinal Cannabis Research  (CMCR) advances science and policy relating to the potential clinical benefits and limitations of cannabis and cannabinoids as medicine.
The CMCR initiated the first therapeutic studies using smoked cannabis in over 20 years, completed key studies regarding the short-term benefits of cannabis for the treatment of neuropathic pain and spasticity, and has numerous active research projects.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s